Naia Rare Diseases Announces Clinical Trial Authorisation (CTA) to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome in the United Kingdom

November 15, 2017
RICHMOND, CA--(Marketwired - November 15, 2017) - Naia Rare Diseases, a biopharmaceutical company developing drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases today announced that it has received Clinical Trial Authorisation ("CTA") from the Medicine and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom to initiate a clinical trial of its long-acting GLP-1 agonist, NB 1001, in adult patients with SBS.

Advertisement

Recent related news

Paradigm Biopharmaceuticals (ASX:PAR) has received results from its phase 2a clinical trial in bone marrow lesions (bone bruising) as a result of an anterior...
6 days ago • Proactive Investors
More than 20 years ago, Taiwanese mother Serena Chen lost her beloved younger son very suddenly. The energetic 20-year-old student was found dead by his desk, as...
4 hours ago • S.China Morning Post
LONDON, November 13, 2017 /PRNewswire/ -- The Global Clinical Trial Supply Forum is to be held at Hurlingham Club, London on the 22 - 24 January 2018 and will...
1 week ago • FinanzNachrichten.de
NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 2 clinical trial of tesevatinib in...
1 week ago • Business Wire
*Business Wire India*AstraZeneca presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in...
3 hours ago • Business Wire India
CARLSBAD, CA--(Marketwired - Nov 13, 2017) - International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company...
1 week ago • Marketwired

You might like